Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987283 | 0.72 | ALDH1A1 (0.43) | — | |
| SCHEMBL3636212 | 0.68 | P2RX3 (0.40) | — | |
| SCHEMBL31644679 | 0.68 | NUAK1 (0.36) | ACHE | |
| SCHEMBL28495109 | 0.68 | MEN1 (0.32) | — | |
| SCHEMBL4378241 | 0.65 | KDM4E (0.35) | — | |
| SCHEMBL22692071 | 0.64 | ALDH1A1 (0.31) | — | |
| SCHEMBL29423714 | 0.64 | ALDH1A1 (0.31) | — | |
| SCHEMBL9689749 | 0.63 | ALOX5 (0.39) | — | |
| SCHEMBL2625336 | 0.62 | — | — | |
| SCHEMBL7410903 | 0.61 | ALOX5 (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | ASTRAZENECA AB (SE) | 2026-05-05 | — | — | US | disclosed |
| CN-119735594-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684300-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684299-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115298182-B | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-112079830-B | Inhibitor containing fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4103566-B1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-05-18 | — | — | US | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20070027156-A1 | Crf antagonists and heterobicyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1666468-A1 | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | ACHE 7/4885 |
| US-20230151013-A1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | KCNC1, KCNJ11, KCNJ1 | ACHE 4420/4885 |
| US-20070027156-A1 | Crf antagonists and heterobicyclic compounds | CRHR2, CRHR1, CRH | ACHE 3319/4885 |
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | KCNC1, TRPC6, KCNH2 | ACHE 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.